Table 1.
Category | Name of Compound | Pharmacological Activities Described in References | Concentration | In Vitro/ In Vivo Model |
---|---|---|---|---|
IC50/EC50/ | ||||
Minimal Inhibitory Concentration (MIC) | ||||
Aporphine | (−)-Anonaine (1) | Cytotoxicity [14] | 8.6–28.9 μM | AGS, DLD1, HA59T, and HepG2 |
Bidebiline E (2) | Anti-bacterial [19] | 6.25 μg/mL | Mycobacterium tuberculosis | |
Inhibition of wnt protein [73] | 20.2 μM | SW480 | ||
Proaporphine | (+)-Stepharine (3) | Cytotoxicity [27] | 9.4–9.9 μg/mL | MCF-7, MDA-MB-231 |
Oxoaporphine | Liriodenine (4) | Cytotoxicity [27,31,74] | 4.46–10.28 μg/mL | MCF-7, MDA-MB-231 |
0.57–2.33 μg/mL | KB, A549, HCT-8, P-388, and L-1210, | |||
Lanuginosine (oxoxylopine) (5) | Cytotoxicity [74] | 1 μg/mL | Unavalible | |
Oxostephanosine (6) | Cytotoxicity [74] | 1 μg/mL | Unavalible | |
Oxostephanine (7) | Cytotoxicity [39] | 1.47–1.73 μg/mL [39] | SPC-A-1 and BEL-7402 | |
Lysicamine (8) | Cytotoxicity [27] | 8.94–16.75 μg/mL | MCF-7, MDA-MB-231 | |
Azafluorene | 5-Hydroxy-6-methoxyonychine (isoursuline) (9) | Cytotoxicity [14] | 21.7 μg/mL | HA59T |
6,8-Dihydroxy-7-methoxy-1-methyl-azafluorenone (10) | Cytotoxicity [75] | 2.64–3.58 μg/mL | A549, GLC4, and adrinamycin-resistance GLC4 | |
Apoptosis [76] | 20–55 μM | HL-60, U937, MOLT-4, MDA-MB-231, and HepG2 | ||
anti-bacterial [75] | 0.78 μg/mL | M. tuberculosis | ||
Polylongine (11) | Cytotoxicity [27] | 9.94–10.41 μg/mL | MCF-7 and MDA-MB-231 | |
Anthraquinones | Marcanine A (12) | Cytotoxicity [77] | 1.53–11.78 μM | BEL-7402, K562, SPCA-1, and SGC-7409 |
Acetogenin | Debilisone B (13) | Anti-bacterial [78] | 25 μg/mL | M. tuberculosis |
Debilisone C (14) | Anti-bacterial [78] | 12.5 μg/mL | Same as above | |
Debilisone E (15) | Anti-bacterial [78,79] | 25 μg/mL | M. tuberculosis | |
64 μg/mL | Morexella catarrhalis | |||
Cytotoxicity [79] | 18.4–40.3 μg/mL | HepG2, A549, HCC-S102, HL-60, and P-388 | ||
Prenylated Benzopyran | Polycerasoidol (16) | Anti-inflammatory [28] | 4.9 μΜ | Inhibition of mononuclear leukocyte adhesion to endothelium |
1-(2-furyl)pentacosa-16,18-diyne (17) | Anti-viral [80] | 43.3 μg/mL | ΔTat/RevMC99 syncytium assay for human immunodeficiency virus (HIV) | |
23-(2-furyl)tricosa-5,7-diynoic acid (18) | Anti-viral [80] | 8.9 μg/mL | Same as above | |
2-substituted furans | 19-(2-furyl)nonadeca-5,7-diynoic acid (19) | Anti-viral [22] | 47 μg/mL | Anti-viral assay against herpes simplex type 1 (HSV-1) |
19-(2-furyl)nonadeca-5-ynoic acid (20) | Anti-viral [22] | 19.4 μg/mL | Same as above | |
21-(2-furyl)heneicosa-14,16-diyne-1-ol (21) | Cytotoxicity [22] | 12.4 μg/mL | NCI-H187 | |
8-Oxoprotoberberine | pendulamine A (22) | Anti-bacterial [18] | 0.02 μg/mL | Gram-positive bacteria |
Corynebacterium hoffmanii and Micrococcus lysodicklycus | ||||
0.2 μg/mL | Staphylococcus aureus | |||
2 μg/mL | Bacillus subtillis | |||
12.5 μg/mL | Streptococcus viridans | |||
20 μg/mL | S. pyogenes | |||
0.02 μg/mL | Gram-negative bacteria | |||
Salmonella typhi | ||||
0.2 μg/mL | S. paratyphi A | |||
2 μg/mL | Klebsiella pneumoniae and Pseudomonas aeruginosa | |||
pendulamine B (23) | Anti-bacterial [18] | 0.02 μg/mL | Gram-positive bacteria | |
C. hoffmanii, S. viridans, and M. lysodicklycus | ||||
0.2 μg/mL | S. aureus, | |||
2 μg/mL | S.s faecalis | |||
20 μg/mL | S. pyogenes | |||
0.2 μg/mL | Gram-negative bacteria | |||
S. paratyphi A and S. typhi | ||||
2 μg/mL | K. pneumoniae | |||
(−)-8-oxo-2,9,10-Trihydroxy-3-methoxyberberine | Cytotoxicity [81] | 24.1 μM | MCF-7 | |
(consanguine B) (24) | 33.5 μM | HeLa | ||
Tetrahydroprotoberberine | (−)-stepholidine (25) | Cytotoxicity [27] | 16.56 μg/mL | MCF-7 |
Amides | N-trans-Feruloyltyramine (26) | Cytotoxicity [27] | 21.17-25.54 μg/mL | MCF-7, MDA-MB-231, HepG2, Hep3B |
N-trans-p-Coumaroyltyramine (27) | Cytotoxicity [27] | 17.35 μg/mL | MCF-7 | |
Sesquiterpenes | Polyalone A (28) | Cytotoxicity [82] | 18.9–24.8 μΜ | HeLa, A549, MCF-7, and HL-60 |
9-Ketocyclocolorenone (29) | Cytotoxicity [82] | 20.5–26.2 μΜ | Same as above | |
Blumenol A(30) | Cytotoxicity [82] | 24.5–28.2 μΜ | Same as above | |
(−)-Methyl dihydrophaseate (31) | Cytotoxicity [82] | 22.6–27.1 μΜ | Same as above | |
Bis-enone (32) | Cytotoxicity [82] | 25.6–30.1 μΜ | Same as above | |
Diterpenoids | Longimide A (33) | Cytotoxicity [83] | 4.12–10.13 μg/mL | KB, MCF-7, A549, and C33A |
44.7 μg/mL | NIH3T3 | |||
labd-13E-en-8-ol-15-oic acid (34) | Cytotoxicity [27] | 15.4–18.33 μg/mL | HepG2 and Hep3B | |
1-naphthaleneacetic-7-oxo-1,2,3,4,4a,7,8,8a-octahydro1,2,4a,5-tetramethyl acid (35) | Cytotoxicity [84] | 50 μM | HL-60 | |
Clerodane diterpenoids | 16-Hydroxycleroda-3,13Z-dien-15,16-olide (36) | Cytotoxicity, apoptosis, anti-cancer [36,43] | Details are in Table 2 | 786-O, A498, HL-60, T24, C6, N18, Caco-2, K562, MCF-7, MDA-MB-231, GBM8401, |
SW620, MOLT-4, HepG2, Hep3B, and A549 | ||||
Anti-inflammatory [27,60,72] | 3.05 ± 1.13 μg/mL | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils. | ||
1–10 μM | LPS-treated RAW264.7 cells | |||
1.6–6.4 mg/kg | irritable bowel disease in mouse model (ADM/DSS-induced colitis) | |||
Anti-bacterial [85] | Gram-negative bacteria | |||
125 μg/mL | S. typhi | |||
250 μg/mL | P. aeruginosa, K. ozaenae, and Proteus mirabilis | |||
Gram-positive bacteria | ||||
7.8 μg/mL | S. aureus | |||
125 μg/mL | S. pyogenes | |||
500 μg/mL | C. hoffmanii | |||
Anti-fungal [85] | 62.5 μg/mL | Aspergillus niger and Trichophyton metagrophyte | ||
250 μg/mL | Candida albicans | |||
16-Hydroxy-cleroda-3,13(14)Z-dien-15,16-olide-2-one (37) | Anti-bacterial [85] | Gram-positive bacteria | ||
15.6 μg/mL | B. subtilis | |||
Anti-inflammatory [27] | 62.5 μg/mL | C. diphtheriae, C. xerosis, and S. aureus | ||
500 μg/mL | C. hoffmanii, and S. pyogenes | |||
7.96 ± 1.78 μg/mL | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | |||
16α-Hydroxycleroda-3,13Z-dien-15,16-olide (38) | Cytotoxicity [14,33,84,86,87,88], | 0.5 μg/mL | P-388 | |
1.2 μg/mL | Mel2 | |||
3.4–8.7 μg/mL | A431, BC1, Col2, HT, KB, drug-resistance KB, LNCaP, Lu1, and ZR75-1 | |||
23.6–26.9 μM | AGS, HA59T | |||
21.28–34.89 μM | HT-29 | |||
A549, MCF-7, HL-60, SMMC-7721, and SW-480 | ||||
Anti-bacterial [20,48,49,89] | Gram-positive bacteria | |||
6.25 μg/mL | S. aureus, Sporothrix schenckii, and Arthrobacter citreus | |||
1.56 μg/mL | B. subtillis, B. polymyxa, and B. pumilus | |||
3.12 μg/mL | B. cereus, B. licheniformis, and Clostridium sp. | |||
Gram-negative bacteria | ||||
0.78 μg/mL | E. coli, P. aeryginosa, and S. typhimurium | |||
1.56 μg/mL | K. aerogenes and Sarcina lutea | |||
3.12 μg/mL | P. putida and Nocardia sp. | |||
Anti-inflammatory [29] | 9.46 ± 0.33 nM | COX1 inhibitory assay | ||
10.34 ± 0.26 nM | COX2 inhibitory assay | |||
14.38 ± 0.32 nM | 5-LOX inhibitory assay | |||
16-Hydroxycleroda-4(18),13 -dien-15,16-olide (39) | Cytotoxicity [27] | 1.97–10.43 μg/mL | MCF-7, MDA-MB-231, HepG2, and Hep3B | |
Anti-inflammatory [29] | 11.85 ± 0.19 nM | COX1 inhibitory assay | ||
8.49 ± 0.55 nM | COX2 inhibitory assay | |||
14.38 ± 0.32 nM | 5-LOX inhibitory assay | |||
Kolavenic acid (40) | cytotoxicity [87] | 1.39–3.34 μg/mL | A549, MCF-7, and HT-29 | |
Anti-bacterial [85] | 31.25 μg/mL | B. subtilis and C. diphtheriae | ||
125 μg/mL | C. hoffmanii and C. xerosis | |||
16-Oxocleroda-3,13E-dien-15-oic acid (41) | Cytotoxicity [10] | 3.1–3.7 μM | MCF-7 and A549 | |
anti-bacterial [85] | Gram-negative bacteria | |||
500 μg/mL | P. aeruginosa, S. typhi, K. ozaenae, K. aerogenes, E. coli, sarcina lutea, Nocardia sp., and P. mirabilis | |||
Gram-positive bacteria | ||||
500 μg/mL | A. citreus, B. cereus, B. licheniformis, B. polymyxa, B. pumilus, B. subtilis, Clostridium sp. S. pyogenes, C. hoffmanii, and S. aureus | |||
Anti-fungal [85] | 62.5 μg/mL | Trichonphyton mentagrophyte | ||
125 μg/mL | A. niger | |||
250 μg/mL | C. albicans | |||
16-Oxocleroda-3,13Z-dien-15-oic acid (polyalthialdoic acid) (42) | Cytotoxicity [87] | 0.552–0.753 μg/mL | A549, MCF-7, and HT-29 | |
16-Oxocelroda-3,13(14)E-dien-15-oic acid methyl ester (43) | Anti-inflammatory [27] | 0.6 ± 0.09 μg/mL | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | |
3β,16α-dihydroxycleroda-4(18),13(14)Z-dien-15,16-olide (44) | Cytotoxicity [33] | 2.2–16μg/mL | P-388, BC1, Col2, LNCaP, Lu1, ZR75-1 | |
12–16 μg/mL | Mel2, A431, HT, and KB | |||
Cytotoxicity [90] | 10.474–24.096 μg/mL | KB, C33A, PA1, MCF-7 | ||
18.564 μg/mL | Vero | |||
anti-bacterial [85] | Gram-positive bacteria | |||
62.5 μg/mL | C. diphtheriae, C. xerosis, and S. pyogenes | |||
125 μg/mL | S. faecalis and C. hoffmanii | |||
250 μg/mL | S. saprophyticus | |||
500 μg/mL | B. subtilis | |||
(−)-3α,16α-dihydroxycleroda-4(18),13(14)Z-dien-15,16-olide (45) | Cytotoxicity [90] | 13.415–29.778 μg/mL | KB, C33A, PA1, and MCF-7 | |
20.345 μg/mL | Vero | |||
Anti-inflammatory [29] | 10.85 ± 0.17 nM | COX1 inhibitory assay | ||
12.82 ± 0.21 nM | COX2 inhibitory assay | |||
16.94 ± 0.56 nM | 5-LOX inhibitory assay | |||
4β,16α-dihydroxycleroda-13(14)Z-en-15,16-olide (46) | Cytotoxicity [33] | 5.1–16 μM | A431. BC1, Col2, HT, LNCaP, Lu1, Mel2, P-388, ZR75-1 | |
16β-Hydroxycleroda-3,13(14)Z-dien-15,16-olide (47) | Anti-oxidant [57] | 23.5 μg/mL | DPPH assay | |
(4→2)-abeo-16(R&S)-2,13Z-clerodadien-15,16-olide-3-al (48) | Cytotoxicity [27] | 2.36–11.89 μg/mL | MCF-7, MDA-MB-231, HepG2, and Hep3B | |
Anti-bacterial [85] | Gram-positive bacteria | |||
31.25 μg/mL | B. subtilis | |||
125 μg/mL | C. hoffmanii, C. xerosis, S. saprophyticus, S. faecalis, and S. pyogenes | |||
Anti-inflammatory [27] | 4.32 ± 0.59 μg/mL | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | ||
(4→2)-abeo-2,13-diformyl-cleroda-2,12E-dien-14-oic acid (49) | Cytotoxicity [91] | 37.35–39.31 μM | HeLa, MCF-7, and A549 | |
16,16-dimethoxy-cleroda-3,13Z-dien-15-oic acid (50) | Cytotoxicity [32] | 22.43 μM | SMMC-7721 | |
Polylauiester A (51) | Cytotoxicity [91] | 33.21–35.65 μM | HeLa, MCF-7, and A549 | |
Polylauiamide B (52) | Cytotoxicity [91] | 28.09–29.25 μM | Same as above | |
Polylauiamide C (53) | Cytotoxicity [91] | 25.01–30.30 μM | Same as above | |
Polylauiamide D (54) | Cytotoxicity [91] | 26.73–28.88 μM | Same as above | |
solidagonal acid (55) | Cytotoxicity [27] | 14.67–18.12 μg/mL | MCF-7 and MDA-MB-231 | |
Anti-bacterial [85] | Gram-positive bacteria | |||
31.25 μg/mL | B. subtilis, C. hoffmanii, and S. saprophyticus | |||
ENT-kaur-16-en-19-oic acid (56) | Anti-viral [92] | 13.7 μg/mL | Anti-syncytium assay against HIV | |
Triterpene | Suberosol (57) | Anti-viral [23] | 3 μg/mL | Inhibition of HIV replication in H9 lymphocytes |
Cytotoxicity [93] | 34.30 μg/mL | SPC-A-1 | ||
15.02 μg/mL | SGC-7901 | |||
24-Methylenecycloartane-3β, 16β, 23β-triol (longitriol) (58) | Cytotoxicity [83] | 10.03–30.88 μg/mL | KB, MCF-7, A549, C33A | |
Cytotoxicity [94] | 19.3–23 μM | MDA-MB-231 and SF-268 | ||
40.3 μM | MRC-5 | |||
Apoptosis [94] | 40 μM | NCI-H460 | ||
Triterpenoids | Friedelin (59) | Anti-bacterial [95] | 5 μg/mL | E. coli and M. tetragenus |
Stigmast-4-ene-6α-ol-3-one (60) | Anti-bacterial [95] | 5 μg/mL | Same as above | |
Flavonoids | Quercetin (61) | Anti-oxidant [54] | 1.56 μg/mL | Trolox equivalent antioxidant capacity (TEAC) assay |
Quercetin-3-O-β-glucopyranoside (62) | Anti-oxidant [54] | 1.56 μg/mL | TEAC assay | |
Rutin (63) | Anti-oxidant [54] | 1.56 μg/mL | TEAC assay | |
Others | Crassalactones A (64) | Cytotoxicity [96] | 0.18–1.9 μg/mL | P-388, KB, Col-2, BCA-1, Lu-1, and ASK |
Crassalactone B (65) | Cytotoxicity [96] | 3.8 μg/mL | P-388 | |
Crassalactone D (66) | Cytotoxicity [96] | 1.1–4 μg/mL | P-388, KB, Col-2, BCA-1, and ASK | |
Aristolactam AII (67) | Cytotoxicity [96] | 2.7 μg/mL | P-388 | |
(+)-Tricinnamate (68) | Cytotoxicity [96] | 3.1 μg/mL | P-388 | |
(+)-Rumphiin (69) | Cytotoxicity [39] | 63.2–187.6 μg/mL | SPC-A-1 and K562 | |
α-Spinasterol (70) | Cytotoxicity [97] | 60.07 ± 7.10 nM/ml | Caco-2 | |
Dehydrogoniothalamin (71) | Anti-inflammatory [65] | 11.6 ± 1.2 μM | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | |
6.8 ± 0.9 μM | inhibition of elastase release by human neutrophils | |||
Goniothalamin (72) | Anti-inflammatory [65] | 8.3 ± 1.4 μM | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | |
15.4 ± 1.1 μM | inhibition of elastase release by human neutrophils | |||
(−)-5-Hydroxy-goniothalamin (71) | Cytotoxicity [65] | 7.9 μM | A549 | |
Anti-inflammatory [65] | 8.1 ± 2.3 μM | Inhibition of fMLP/CB-induced superoxide anion production by human neutrophils | ||
14.6 ± 0.7 μM | Inhibition of elastase release by human neutrophils | |||
Octadeca-9,11,13-triynoic acid (72) | Anti-bacterial [19] | 6.25 μg/mL | M. tuberculosis | |
Cytotoxicity [19] | 13 μg/mL | BC1 | ||
α-Humulene (73) | Anti-bacterial [19] | 6.25 μg/mL | M. tuberculosis | |
F2 peptide | Apoptosis [98] | 30 μg/mL | A549 and HeLa |
Index of cell lines. Lung cancer: A549, GLC4, NCI-H460, NCI-H187, Lu-1, and SPCA-1. Gastric cancer: AGS, SGC-7409, and SGC-7901. Liver cancer: HA59T, HepG, Hep3B, BEL-7402, HCC-S102, and SMMC-7721. Breast cancer: BC1, BCA-1, MCF-7, MDA-MB-231, and ZR75-1. Uterine and cervix cancer: C33A and HeLa. Skin cancer: Mel2 and A431. Blood cancer: HL-60, K562, MOLT-4, and U937. Lympoma: P-388 and HT. Head and neck cancer: KB. Urothelial cancer: 786-O, A498, and T24. Prostate cancer: LNCaP. Brain cancer: ASK, SF-268, GBM8401, C6, and N18. Colon cancer: Col-2, HT-29, SW-480, Caco-2, DLD1, and SW620. Normal immortalized cell lines: NIH3T3, RAW264.7, Vero, and MRC-5.